Editas Medicine Reports on Recent Progress and 2017 Goals

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
142
Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

-    Company Achieves In Vivo Proof-of-Editing in the Retina of Non-Human Primates    -  

-    Unparalleled Genome Editing Platform Includes Cpf1 and Advanced Forms of Cas9    -

CAMBRIDGE, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 11, 2017 at 11:30am (PST) at the 35 th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (NASDAQ: EDIT ) President and CEO Katrine Bosley will outline the Company’s progress on developing medicines and building the leading genomic medicine company.  In her remarks, Ms. Bosley will discuss several components of the Company’s growth, including:

  • Driving Editas Medicine’s unparalleled platform for genome editing medicines.   As the only company with access to the CRISPR genome editing systems Cas9, advanced forms of Cas9, and the novel Cpf1 genome editing system, Editas Medicine has the potential to treat the broadest range of diseases through efficient editing of nearly any genetic target.  
  • Advancing a pipeline strategy to enable successful product development in the years ahead .  For Editas Medicine’s LCA10 program, this includes achieving the first in vivo proof-of-editing in the retina of non-human primates, as well as the Company’s goal to submit an IND for the LCA10 program by the end of 2017. In addition, Ms. Bosley will discuss recent progress in achieving consistent, durable editing in hematopoietic stem cells and high efficiency editing of CAR-T cells.  
  • Building the business for the long term by assembling the capabilities to fully develop and commercialize important medicines.   This includes aggressively developing valuable partnerships, robust financial resources, an unmatched patent position, and an outstanding team and culture to drive Editas Medicine’s bold vision for years to come.

“We had a very strong 2016 that lays the important groundwork to make 2017 a transformative year for Editas Medicine,” said Ms. Bosley.  “We are focused on driving our unparalleled platform and executing our pipeline strategy while building the company into the genomic medicine leader.  At Editas Medicine, we have a bold vision and are excited about unlocking the power of CRISPR to design and develop genome editing therapies for patients suffering from genetically-defined and genetically-treatable diseases.”

In addition, Ms. Bosley will outline the Company’s 2017 goals, including driving the following critical initiatives:

  • Submitting an IND for the LCA10 program by year-end 2017;
  • Initiating an LCA10 clinical natural history study in mid-2017;
  • Achieving preclinical proof-of-concept for additional programs;
  • Establishing additional alliances aligned with the Company’s business development strategy; and
  • Continuing to build an outstanding organization and culture.

About Editas Medicine Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Forward-Looking Statements  This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company’s goals of submitting of an IND for the LCA10 program by year-end 2017, initiating an LCA10 natural history study in mid-2017, achieving preclinical proof-of-concept for additional programs and establishing alliances.  The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Editas Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com Editas Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 116

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 127

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 176

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 57

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 193

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading

Top 5 Most Recently Viewed Articles

Riyadh Gears Up for UNIDO 2025: A Step Towards Sustainable Industry

Updated Category News Views 180

Riyadh Gears Up for UNIDO 2025 Riyadh is on the verge of an exciting global event as it prepares to host the 21st Session of the United Nations Industrial Development Organization (UNIDO) General Conference. This significant summit is scheduled to happen at the King Abdulaziz International Conference Centre, where leaders from various sectors will gather to discuss the...

Continue Reading
Deer Park Road Strategizes for Growth Amid CRE Market Changes

Updated Category News Views 205

Deer Park Road Strategies in a Changing CRE Landscape Deer Park Road Management Company, LP, a notable $2.8 billion alternative asset management firm, is honing in on emerging prospects within the challenging environment of the Commercial Mortgage-Backed Securities (CMBS) market. The firm’s extensive expertise enables them to consistently identify potential value during...

Continue Reading
iRobot Corporation Faces Legal Challenges Amid Financial Struggles

Updated Category News Views 141

Legal Investigations into iRobot Corporation Investors are currently facing uncertainties surrounding iRobot Corporation as it faces legal scrutiny. The well-respected law firm Faruqi & Faruqi, LLP has initiated investigations regarding potential legal claims on behalf of investors who suffered significant losses. Who to Contact James (Josh) Wilson, a partner at Faruqi &...

Continue Reading
Dr. Andrea Fuyuko Honda Recognized for Medical Innovation Excellence

Updated Category News Views 385

Dr. Andrea Fuyuko Honda's Recent Recognition Dr. Andrea Fuyuko Honda has been prominently recognized as a Pinnacle Professional Member within an elite circle of excellence. This accolade reflects her significant contributions to the field as a Leading Medical Communications Expert and Innovator. With a career spanning over fifteen years, Dr. Honda has demonstrated...

Continue Reading
Centene Corporation Faces Securities Fraud Legal Action

Updated Category News Views 206

Centene Corporation Faces New Lawsuit Over Securities Fraud Investors of Centene Corporation, known by the ticker symbol CNC, have found themselves at the center of a securities fraud lawsuit. Recently, a leading law firm announced the initiation of legal action against Centene Corporation and some of its senior executives. This lawsuit stems from alleged violations of...

Continue Reading